Please ensure Javascript is enabled for purposes of website accessibility

Sanofi Gets Backing From U.S. Government to Develop a COVID-19 Vaccine

By Brian Orelli, PhD – Updated Feb 18, 2020 at 1:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The French drugmaker joins a host of other companies trying to develop vaccines and treatments for the coronavirus.

Sanofi (SNY 0.05%) is teaming up with the U.S. government in its attempt to develop a vaccine for the COVID-19 coronavirus. Through the Biomedical Advanced Research and Development Authority (BARDA), the government will support those efforts, although financial details of the agreement weren't disclosed.

Protein Sciences, which Sanofi acquired in 2017, has a bit of a head start, having worked on a vaccine for SARS, which is caused by another coronavirus. That treatment didn't get off the ground because SARS petered out just a couple of years after it emerged in 2002, but preclinical work showed that Sanofi's SARS vaccine candidate produced partial protection in animals challenged with the virus.

People on the sidewalk wearing face masks

Image source: Getty Images.

Rather than growing a virus and then making it inactive to produce a vaccine, Sanofi's vaccine technology uses DNA from the virus to produce proteins found on its surface, which can then be used to stimulate the immune system to develop antibodies against the virus itself. Not only is this a potentially quicker way to develop vaccines,  this technique also makes it easier to produce those vaccines in large quantities.

Sanofi is just one of a host of drug companies hunting for a COVID-19 vaccine. BARDA is also supporting Johnson & Johnson's (JNJ -0.71%) efforts. Last month, Inovio Pharmaceuticals (INO 2.68%) received a $9 million grant from the Coalition for Epidemic Preparedness Innovations, and the biotech has already disclosed it has a candidate vaccine that it hopes to move into clinical trials as early as this summer. Novavax (NVAX -1.99%) could also be in the hunt, although the vaccine expert hasn't jumped on the bandwagon publicly with press releases on the subject.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$38.02 (0.05%) $0.02
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$163.36 (-0.71%) $-1.17
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.20 (-1.99%) $0.37
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.73 (2.68%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.